4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report sent to investors on Saturday,Weiss Ratings reports.

FDMT has been the subject of several other research reports. Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Bank of America lowered their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Chardan Capital lowered their price target on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Morgan Stanley lowered their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday, January 13th. Finally, Leerink Partners lowered their price target on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $30.63.

4D Molecular Therapeutics Price Performance

FDMT stock opened at $3.92 on Friday. 4D Molecular Therapeutics has a 1-year low of $3.58 and a 1-year high of $36.25. The firm has a fifty day moving average price of $4.69 and a two-hundred day moving average price of $7.39. The firm has a market cap of $181.50 million, a price-to-earnings ratio of -1.38 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). As a group, analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in 4D Molecular Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company’s stock worth $15,933,000 after purchasing an additional 92,791 shares during the period. State Street Corp lifted its holdings in 4D Molecular Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company’s stock valued at $22,879,000 after acquiring an additional 37,232 shares during the last quarter. Millennium Management LLC lifted its holdings in 4D Molecular Therapeutics by 1,607.1% in the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock valued at $7,913,000 after acquiring an additional 1,337,497 shares during the last quarter. Redmile Group LLC lifted its holdings in 4D Molecular Therapeutics by 17.6% in the 3rd quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock valued at $13,643,000 after acquiring an additional 188,655 shares during the last quarter. Finally, Braidwell LP lifted its holdings in 4D Molecular Therapeutics by 231.7% in the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after acquiring an additional 855,990 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.